Sacerdoti D, Serianni G, Gaiani S, Bolognesi M, Bombonato G, Gatta A
Department of Clinical and Experimental Medicine, Clinica Medica 5, University of Padova, Italy.
J Ultrasound. 2007 Mar;10(1):12-21. doi: 10.1016/j.jus.2007.02.007. Epub 2007 Apr 16.
Portal vein thrombosis (PVT) is a rare cause of portal hypertension. Its diagnosis has been facilitated by improvements in imaging techniques, in particular Doppler sonography. The prevalence is about 1% in the general population, but much higher rates are observed in patients with hepatic cirrhosis (7%, range 0.6-17%), particularly those who also have hepatocellular carcinoma (HCC) (35%). The most common causes of PVT are myeloproliferative disorders, deficiencies of anticoagulant proteins, prothrombotic gene mutations, cirrhosis with portal hypertension, and HCC. Its development often requires the presence of two or more risk factors (local and/or systemic), e.g., a genetically determined thrombophilic state plus an infectious episode or abdominal surgery. It is clinically useful to distinguish between cirrhotic and noncirrhotic forms. Portal vein thrombosis is also traditionally classified as acute or chronic, but this distinction is often difficult. Color Doppler ultrasound is the first-line imaging study for diagnosis of PVT; magnetic resonance angiography and CT angiography are valid alternatives. The main complications are ischemic intestinal necrosis (in acute PVT) and esophageal varices (in chronic cases); the natural history of the latter differs depending on whether or not the thrombosis is associated with cirrhosis. The treatment of choice for PVT has never been adequately investigated. It is currently based on the use of anticoagulants associated, in some cases, with thrombolytics, but experience with the latter agents is too limited to draw any definite conclusions. In chronic thrombosis (even forms associated with cirrhosis), anticoagulant therapy is recommended and possibly, beta-blockers as well. Naturally, treatment of the underlying pathology is essential.
门静脉血栓形成(PVT)是门静脉高压的一种罕见病因。成像技术的改进,尤其是多普勒超声检查,促进了其诊断。在普通人群中,其患病率约为1%,但在肝硬化患者中观察到的患病率要高得多(7%,范围为0.6 - 17%),尤其是那些同时患有肝细胞癌(HCC)的患者(35%)。PVT最常见的病因是骨髓增殖性疾病、抗凝蛋白缺乏、促血栓形成基因突变、伴有门静脉高压的肝硬化以及HCC。其发生通常需要存在两种或更多种危险因素(局部和/或全身),例如,遗传决定的血栓形成倾向状态加上感染发作或腹部手术。区分肝硬化型和非肝硬化型在临床上很有用。传统上,门静脉血栓形成也分为急性或慢性,但这种区分往往很困难。彩色多普勒超声是诊断PVT的一线影像学检查;磁共振血管造影和CT血管造影也是有效的替代方法。主要并发症是缺血性肠坏死(急性PVT时)和食管静脉曲张(慢性病例时);后者的自然病程因血栓形成是否与肝硬化相关而有所不同。PVT的首选治疗方法从未得到充分研究。目前基于使用抗凝剂,在某些情况下还联合使用溶栓剂,但后者的经验有限,无法得出任何明确结论。对于慢性血栓形成(即使是与肝硬化相关的类型),建议进行抗凝治疗,可能还需要使用β受体阻滞剂。当然,治疗潜在的病理状况至关重要。